MIV-711: Ph IIa completed enrollment

Medivir completed enrollment of 244 patients with knee joint OA in the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial evaluating 100 and 200 mg oral MIV-711 once daily for 6 mo...